Published in J Neurosci on September 13, 2006
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation (2008) 3.19
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06
Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis (2009) 2.49
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 2.23
Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci (2008) 1.85
Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation (2008) 1.65
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J Neurosci (2008) 1.48
The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci (2009) 1.42
The immunology of neurodegeneration. J Clin Invest (2012) 1.41
TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res (2008) 1.40
Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal (2010) 1.34
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One (2012) 1.27
The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol (2008) 1.26
Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain (2011) 1.25
Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther (2008) 1.19
Glial connexins and gap junctions in CNS inflammation and disease. J Neurochem (2008) 1.17
Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev (2015) 1.13
Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther (2010) 1.10
TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol (2015) 1.10
Regulator of G-protein signaling-10 negatively regulates NF-κB in microglia and neuroprotects dopaminergic neurons in hemiparkinsonian rats. J Neurosci (2011) 1.08
Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology (2012) 1.07
The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation (2008) 1.06
1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimers Dis (2013) 1.05
Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro (2013) 1.05
The specificity of neuroprotection by antioxidants. J Biomed Sci (2009) 1.05
Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood (2010) 1.05
Regulation of microglia effector functions by tumor necrosis factor signaling. Glia (2011) 1.04
Genetic analysis of the role of tumor necrosis factor receptors in functional outcome after traumatic brain injury in mice. J Neurotrauma (2010) 1.03
The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 1.03
Progranulin does not bind tumor necrosis factor (TNF) receptors and is not a direct regulator of TNF-dependent signaling or bioactivity in immune or neuronal cells. J Neurosci (2013) 1.01
Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades. J Neuroinflammation (2010) 1.00
Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener (2015) 0.98
Innate inflammation in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 0.96
Parkinson's disease and systemic inflammation. Parkinsons Dis (2011) 0.96
Psychological stress in adolescent and adult mice increases neuroinflammation and attenuates the response to LPS challenge. J Neuroinflammation (2012) 0.93
Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease? Front Cell Neurosci (2013) 0.93
Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis (2015) 0.93
Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia. J Neurochem (2009) 0.92
Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci (2015) 0.92
Differential roles of TNFR1 and TNFR2 signaling in adult hippocampal neurogenesis. Brain Behav Immun (2013) 0.92
Tumor necrosis factor-alpha (TNF-alpha) regulates Toll-like receptor 2 (TLR2) expression in microglia. J Neurochem (2007) 0.92
Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies. Biomed Res Int (2015) 0.92
Glial tumor necrosis factor alpha (TNFα) generates metaplastic inhibition of spinal learning. PLoS One (2012) 0.92
Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther (2011) 0.92
The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses. J Immunol (2008) 0.91
IL-27 inhibits OSM-mediated TNF-alpha and iNOS gene expression in microglia. Glia (2010) 0.91
Proteolytic activation of proapoptotic kinase protein kinase Cδ by tumor necrosis factor α death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation (2012) 0.91
Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. Parkinsons Dis (2011) 0.91
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. J Neuroinflammation (2014) 0.90
Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab Dispos (2010) 0.90
Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse. J Neuroinflammation (2012) 0.90
Calcium dysregulation and neuroinflammation: discrete and integrated mechanisms for age-related synaptic dysfunction. Ageing Res Rev (2013) 0.89
Ceramide sphingolipid signaling mediates Tumor Necrosis Factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Mol Neurodegener (2012) 0.89
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci (2012) 0.89
α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease. Toxicol Sci (2014) 0.88
Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND. J Neuroimmune Pharmacol (2013) 0.87
Effects of naringin, a flavanone glycoside in grapefruits and citrus fruits, on the nigrostriatal dopaminergic projection in the adult brain. Neural Regen Res (2014) 0.85
Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS One (2011) 0.85
The role of the LRRK2 gene in Parkinsonism. Mol Neurodegener (2014) 0.85
Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. J Neuroinflammation (2014) 0.84
The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. J Neuroinflammation (2011) 0.84
Redox regulation of NF-κB p50 and M1 polarization in microglia. Glia (2014) 0.83
Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease. Exp Neurol (2007) 0.83
RGS10 exerts a neuroprotective role through the PKA/c-AMP response-element (CREB) pathway in dopaminergic neuron-like cells. J Neurochem (2012) 0.83
Isolation of murine postnatal brain microglia for phenotypic characterization using magnetic cell separation technology. Methods Mol Biol (2013) 0.82
Aqueous extract from the Withania somnifera leaves as a potential anti-neuroinflammatory agent: a mechanistic study. J Neuroinflammation (2016) 0.82
Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats. PLoS One (2012) 0.82
Antidepressant-like effect of celecoxib piroxicam in rat models of depression. J Neural Transm (Vienna) (2014) 0.81
Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Mol Pharm (2013) 0.81
Microglial phenotypes in Parkinson's disease and animal models of the disease. Prog Neurobiol (2016) 0.80
RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells. Neurobiol Dis (2013) 0.80
Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. J Parkinsons Dis (2014) 0.80
Essential control of mitochondrial morphology and function by chaperone-mediated autophagy through degradation of PARK7. Autophagy (2016) 0.80
Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J Neuroinflammation (2013) 0.80
6-Mercaptopurine attenuates tumor necrosis factor-α production in microglia through Nur77-mediated transrepression and PI3K/Akt/mTOR signaling-mediated translational regulation. J Neuroinflammation (2016) 0.79
Parkinson's disease and enhanced inflammatory response. Exp Biol Med (Maywood) (2015) 0.79
Effects of paeonol on anti-neuroinflammatory responses in microglial cells. Int J Mol Sci (2015) 0.78
Bid signal pathway components are identified in the temporal cortex with Parkinson disease. Neurology (2012) 0.78
Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. J Neuroinflammation (2016) 0.77
The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation. Parkinsons Dis (2011) 0.77
The mechanism of antidepressant-like effects of piroxicam in rats. J Pharmacol Pharmacother (2015) 0.77
Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target. Mol Neurobiol (2016) 0.77
AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease. PLoS One (2014) 0.76
Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease. Antioxid Redox Signal (2016) 0.76
Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2. Exp Neurobiol (2016) 0.76
β-arrestin protects neurons by mediating endogenous opioid arrest of inflammatory microglia. Cell Death Differ (2013) 0.76
Papaverine inhibits lipopolysaccharide-induced microglial activation by suppressing NF-κB signaling pathway. Drug Des Devel Ther (2016) 0.75
Human pluripotent stem cell derived midbrain PITX3(eGFP/w) neurons: a versatile tool for pharmacological screening and neurodegenerative modeling. Front Cell Neurosci (2015) 0.75
The TNFα-Transgenic Rat: Hippocampal Synaptic Integrity, Cognition, Function, and Post-Ischemic Cell Loss. PLoS One (2016) 0.75
Behavioral and monoamine perturbations in adult male mice with chronic inflammation induced by repeated peripheral lipopolysaccharide administration. Behav Brain Res (2016) 0.75
Olfactory impairment is related to REM sleep deprivation in rotenone model of Parkinson's disease. Sleep Sci (2017) 0.75
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec (1991) 11.44
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79
Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci (2005) 5.93
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A (2005) 3.83
Cytokines and acute neurodegeneration. Nat Rev Neurosci (2001) 3.70
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci (2001) 3.50
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron (2005) 3.30
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.18
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther (2002) 2.58
TNF receptor subtype signalling: differences and cellular consequences. Cell Signal (2002) 2.57
Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J Biol Chem (1997) 2.53
Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J Neurosci Methods (1985) 2.52
Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol (1998) 2.20
Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell (1993) 2.17
Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther (2000) 2.14
Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des (2005) 1.87
Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci (2002) 1.87
Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol (2005) 1.82
Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J (2002) 1.79
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology (2005) 1.66
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J (2006) 1.61
Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest (2003) 1.58
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci (1999) 1.58
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 1.48
Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal (2005) 1.47
Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation (2004) 1.43
Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat. J Comp Neurol (1993) 1.41
Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol (2001) 1.40
Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord (2005) 1.39
Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem (2004) 1.38
The Toll-like receptors: analysis by forward genetic methods. Immunogenetics (2005) 1.31
Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am J Pathol (2005) 1.21
Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord (2005) 1.20
Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res (2002) 1.18
Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-alpha reveals an essential role for TNF. J Leukoc Biol (2003) 1.08
Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. J Neural Transm (Vienna) (2004) 1.07
Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm (Vienna) (2000) 1.06
TNF-alpha antibody infusion impairs survival of stroke-generated neuroblasts in adult rat brain. Exp Neurol (2005) 1.03
Mesencephalic type 1 astrocytes rescue dopaminergic neurons from death induced by serum deprivation. J Neurosci (1994) 1.02
Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease. Neurosci Lett (2001) 1.00
The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine (2003) 1.00
Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp Neurol (2002) 0.99
Effects of cytokines on microglial phenotypes and astroglial coupling in an inflammatory coculture model. Glia (2005) 0.95
Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. Neurosci Lett (1999) 0.95
TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp Neurol (1996) 0.94
Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. Cell Immunol (1991) 0.92
Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism Relat Disord (2005) 0.90
Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. Neurosci Lett (2004) 0.89
TNF-alpha expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior. Neurosci Lett (1997) 0.84
Brain proteome of mice lacking the receptors for tumor necrosis factor alpha. Proteomics (2004) 0.84
Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol (2006) 0.84
Neuronal and glial gamma-aminobutyric acid+ transporters are distinct proteins. FEBS Lett (1992) 0.78
The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science (2011) 7.07
Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci (2004) 5.70
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation (2008) 3.19
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 2.23
Carbon nanotube coating improves neuronal recordings. Nat Nanotechnol (2008) 2.16
Gamma-secretase activity is dispensable for mesenchyme-to-epithelium transition but required for podocyte and proximal tubule formation in developing mouse kidney. Development (2003) 1.87
Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci (2008) 1.85
Gammadelta intraepithelial lymphocytes are essential mediators of host-microbial homeostasis at the intestinal mucosal surface. Proc Natl Acad Sci U S A (2011) 1.80
Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci (2007) 1.71
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J Neurosci (2008) 1.48
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 1.48
Changes in motoneuron properties and synaptic inputs related to step training after spinal cord transection in rats. J Neurosci (2007) 1.46
Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol (2007) 1.41
MUC17, a novel membrane-tethered mucin. Biochem Biophys Res Commun (2002) 1.39
TH17 cell differentiation is regulated by the circadian clock. Science (2013) 1.37
Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS One (2006) 1.32
Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain (2011) 1.25
The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today (2009) 1.24
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol (2008) 1.22
Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol (2009) 1.20
Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther (2008) 1.19
Notch1 signaling influences v2 interneuron and motor neuron development in the spinal cord. Dev Neurosci (2006) 1.17
Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol (2011) 1.16
Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-kappa B. J Biol Chem (2002) 1.11
Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther (2010) 1.10
Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Brain (2011) 1.10
Regulator of G-protein signaling-10 negatively regulates NF-κB in microglia and neuroprotects dopaminergic neurons in hemiparkinsonian rats. J Neurosci (2011) 1.08
The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation (2008) 1.06
Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro (2013) 1.05
Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood (2010) 1.05
Quantitative analysis of the detergent-insoluble brain proteome in frontotemporal lobar degeneration using SILAC internal standards. J Proteome Res (2012) 1.05
Regulation of microglia effector functions by tumor necrosis factor signaling. Glia (2011) 1.04
The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 1.03
Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res (2010) 1.02
Progranulin does not bind tumor necrosis factor (TNF) receptors and is not a direct regulator of TNF-dependent signaling or bioactivity in immune or neuronal cells. J Neurosci (2013) 1.01
Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. J Allergy Clin Immunol (2012) 0.99
Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy? Front Biosci (2008) 0.98
Rehabilitation Research at the National Institutes of Health: Moving the Field Forward (Executive Summary). Am J Phys Med Rehabil (2017) 0.98
Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS One (2011) 0.97
Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guérin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Infect Dis (2009) 0.95
Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. J Hepatol (2010) 0.95
Psychological stress in adolescent and adult mice increases neuroinflammation and attenuates the response to LPS challenge. J Neuroinflammation (2012) 0.93
Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease? Curr Neurol Neurosci Rep (2012) 0.93
The neuro-glial properties of adipose-derived adult stromal (ADAS) cells are not regulated by Notch 1 and are not derived from neural crest lineage. PLoS One (2008) 0.93
Roles of soluble and membrane TNF and related ligands in mycobacterial infections: effects of selective and non-selective TNF inhibitors during infection. Adv Exp Med Biol (2011) 0.92
Modification of spasticity by transcutaneous spinal cord stimulation in individuals with incomplete spinal cord injury. J Spinal Cord Med (2013) 0.91
Ceramide sphingolipid signaling mediates Tumor Necrosis Factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Mol Neurodegener (2012) 0.89
TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. Adv Exp Med Biol (2011) 0.89
Microglia isolation from adult mouse brain. Methods Mol Biol (2013) 0.86
Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiol Dis (2013) 0.86
Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis (2013) 0.86
Critical role of regulator G-protein signaling 10 (RGS10) in modulating macrophage M1/M2 activation. PLoS One (2013) 0.86
The duality of TNF signaling outcomes in the brain: potential mechanisms? Exp Neurol (2011) 0.84
RGS10 exerts a neuroprotective role through the PKA/c-AMP response-element (CREB) pathway in dopaminergic neuron-like cells. J Neurochem (2012) 0.83
Conservative management of priapism in acute spinal cord injury. Urology (2005) 0.83
Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease. Exp Neurol (2007) 0.83
Synchronous stimulation and monitoring of soleus H reflex during robotic body weight-supported ambulation in subjects with spinal cord injury. J Rehabil Res Dev (2008) 0.83
Isolation of murine postnatal brain microglia for phenotypic characterization using magnetic cell separation technology. Methods Mol Biol (2013) 0.82
Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol (2014) 0.82
Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats. PLoS One (2012) 0.82
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. J Inflamm Res (2008) 0.81
Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J Neuroinflammation (2013) 0.80
Allergic lung inflammation is mediated by soluble tumor necrosis factor (TNF) and attenuated by dominant-negative TNF biologics. Am J Respir Cell Mol Biol (2011) 0.79
From contemporary rehabilitation to restorative neurology. Clin Neurol Neurosurg (2012) 0.78
Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family. Adv Exp Med Biol (2011) 0.77
Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19. MAbs (2014) 0.77
Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb. Immunol Lett (2012) 0.77
Inflammation in neuropsychiatric disease. Neurobiol Dis (2009) 0.77
Rational optimization of proteins as drugs: a new era of 'medicinal biology'. Drug Discov Today (2004) 0.76
Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. JCI Insight (2017) 0.75
Rehabilitation Research at the National Institutes of Health:: Moving the Field Forward (Executive Summary). Phys Ther (2017) 0.75
Rehabilitation Research at the National Institutes of Health Moving the Field Forward (Executive Summary). Rehabil Psychol (2017) 0.75
Clinical features of brain motor control and influence in upper motor neuron dysfunction. Clin Neurol Neurosurg (2012) 0.75